Difficulty: Medium
Average Score: 79%
Practice
A 13-year-old girl presents with acute myeloid leukemia (AML) and a WBC count of 120,000/mm3. Cytogenetics reveals a normal karyotype, and fluorescence in situ hybridization (FISH) tests for inv(16), t(8;21), t(15;17); 11q23 abnormalities; monosomy 7; and 5q deletion are negative. Molecular testing is negative for mutations in FLT3, NPM1, and CEBPA. She is treated with 10 days of daunorubicin, AraC, and gemtuzumab for induction therapy. On day 30, she recovers counts, and a bone marrow aspiration shows 2.2% leukemic blasts by flow cytometry. She receives a second course of treatment with daunorubicin and AraC, and her marrow is now in morphologic remission and is MRD-negative by flow cytometry. She has no HLA-matched siblings, but an unrelated donor search reveals a large number of potential matches. Which course of treatment is most likely to result in the best outcome?
Correct answer
C
Rationale
The correct answer is C: Give one more course of intensification chemotherapy and then perform a matched unrelated donor HSCT. In this scenario, the patient achieved morphologic remission and MRD-negative status after the second course of chemotherapy. Performing a matched unrelated donor HSCT can provide the best chance for long-term disease control and potential cure by replacing the patient's hematopoietic system with healthy donor cells, reducing the risk of relapse. This approach combines the benefits of achieving remission with chemotherapy and the potentially curative effects of allogeneic HSCT. The other choices are suboptimal: A may lead to excessive toxicity, B may not be as effective in preventing relapse, and D may not be as curative as HSCT in this high-risk case.